Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions

Elizabeth K.S. Barksdale

LUNGevity Foundation, Chicago, IL

Wendy Selig

WSCollaborative, McLean, VA

Willyanne DeCormier Plosky

Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA

Erin Miller

Keri McDonough

Independent Patient Advocacy Consultant, Jackson Heights, NY

Chelsea Backler

Oncology Nursing Society, Pittsburgh, PA

Elizabeth George

Labcorp, Burlington, NC

Mark E. Fleury

American Cancer Society Cancer Action Network, Washington, DC

Marc J. Taylor

Pfizer, New York, NY

Diana E. Pankevich

Pfizer, New York, NY

Jim Murphy

Greenphire, King of Prussia, PA

Kristin Hermann

Scout Clinical, Dallas, TX

Leigh Ann Davis

Pfizer, New York, NY

Gissoo DeCotiis

Daiichi Sankyo, Basking Ridge, NJ

Cecile Gonzalez-Cerimele

Eli Lilly & Company, Indianapolis, IN

Colleen Cook

Mirati Therapeutics, San Diego, CA

Sandra Shaw

Mirati Therapeutics, San Diego, CA

Luke Gelinas

Advarra, Columbia, MD

Dana L. Dornsife

Lazarex Cancer Foundation, Danville, CA

Barbara E. Bierer

The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital, Boston, MA

David E. Gerber